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Abstract
Loss of ATM, a key protein regulating DNA repair increases sensitivity to DNA damaging agents such as
oxaliplatin chemotherapy. We describe the prevalence of ATM IHC loss in a large cohort of patients with
metastatic colorectal cancer and its correlation with clinical parameters such as association with other key
biomarkers in colon cancer and survival.
Background: Loss of ataxia telangiectasia mutated (ATM), a key protein regulating DNA repair signaling, has been
suggested to increase sensitivity to DNA damaging agents. We conducted a study analyzing the loss of ATM protein
expression in colorectal cancer and correlated this with clinical outcomes. Materials and Methods: The clinical
outcomes data and tumor samples from metastatic colorectal cancer patients referred to the Royal Marsden Hospital
Drug Development Unit (United Kingdom) from 2012 to 2016 and providing consent for a molecular characterization
study were analyzed. Immunohistochemistry (IHC) slides were assessed by a pathologist for nuclear staining intensity
of ATM and semiquantitatively scored. ATM loss was deﬁned as a nuclear H-score of  10. Results: Of 223 colorectal
cancer samples, ATM IHC loss was identiﬁed in 17 (8%). ATM loss was independent of the RAS and RAF mutational
status. ATM loss was associated with superior overall survival after ﬁrst-line oxaliplatin-based therapy (49 vs.
32 months; hazard ratio [HR], 2.52) but not with irinotecan-based therapy (24 vs. 33 months; HR, 0.72). ATM loss was
not prognostic for survival from the diagnosis (50 vs. 44 months; HR, 1.43). Conclusion: ATM could be considered a
biomarker for the development of novel DNA repair targeting agents and treatment of colorectal cancer.
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Ataxia telangiectasia mutated (ATM) and ATM and rad3-related
(ATR) kinase are key checkpoint proteins of the DNA damage
response pathway.1 Preclinical models have suggested that
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hypothesized from data from phase I clinical trials that ATM deﬁ-
ciency in colorectal cancer would portend sensitivity to DNA
damaging chemotherapeutic agents such as oxaliplatin and irinote-
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Figure 1 Ataxia Telangiectasia Mutated (ATM) Immunohistochemistry (IHC). IHC Images of Colorectal Cancer (Original
Magniﬁcation, 320) Showing Tumor Cell Nuclear H-score of (A) 0 (With Stromal Staining), (B) 10, (C) 90, and (D) 300expression in colorectal cancer and corroboration with the clinical
data and outcomes have not been reported previously.
Materials and Methods
Patient Cohort
Colorectal cancer patients who were referred to the Royal
Marsden Hospital, Drug Development Unit (United Kingdom)
from 2012 to 2016 and provided consent for participation to a
molecular characterization study were identiﬁed as potential
candidates. The clinical data for all patients were collected retro-
spectively from the electronic medical records. The information
collected included patient demographic data and treatment history
for colorectal cancer.
Ethics Approval and Consent to Participate
All patients provided written informed consent and were enrolled
in accordance with institutional protocols approved by the Royal
Marsden NHS Foundation Trust Hospital (London, UK) ethics
review committee (approval no. CCR3171). The study was per-
formed in accordance with the Declaration of Helsinki.
ATM Immunohistochemistry
Formalin-ﬁxed, parafﬁn-embedded (FFPE) samples were ob-
tained from primary tumor biopsy specimens, surgical resection
specimens, and colorectal cancer metastases of the lymph nodes or
viscera (needle biopsy samples). ATM protein expression was
determined by immunohistochemistry (IHC) on 3- to 4-mM-thick
FFPE sections using a rabbit monoclonal anti-ATM antibody Y170
at 1:400 (catalog no. ab32420; Abcam plc, Cambridge, UK).
The IHC slides were assessed by a pathologist, who was unaware of
the patients’ clinical characteristics, sequencing ﬁndings, and out-
comes data. Nuclear staining was semiquantitatively assessed using an
H-score formula: 3 times the percentage of strongly staining cells and
2 times the percentage ofmoderately staining cells, and the percentage
of weakly staining cells, for a range of 0 to 300.5 A dichotomous
classiﬁcation systemwas devised in which cases were considered ATM
negative if they either showed a complete absence of ATM staining or
weak intensity staining in  10% cancer cells (H-score  10).
Next Generation Sequencing
DNA was extracted from FFPE blocks using the FFPE Tissue
DNA kit (Qiagen). DNA was quantiﬁed with the Quant-iT high-sensitivity PicoGreen double-stranded DNA Assay Kit (Invitrogen),
and DNA quality control was assessed using the Illumina FFPE QC
kit (catalog no. WG-321-1001), as described previously.6
Libraries were constructed from 40 ng of DNA using a
customized Generead DNAseq Mix-n-Match, version 2, panel
(Qiagen) covering 6025 amplicons (398,702 bp) across 113 genes.7
The libraries were pooled and run using the MiSeq Sequencer
(Illumina) at a minimum of 500. FASTQ ﬁles were generated
using the Illumina MiSeq Reporter, version 2.5.1.3. Sequence
alignment and mutation calling were performed using BWA tools
and the GATK variant annotator by the Qiagen GeneRead targeted
exon enrichment panel data analysis web portal. Variant calls
(variant call format ﬁles) were ﬁltered using Galaxy tools. Somatic
variant calls were manually inspected in an integrated genome
viewer (Broad Institute, Cambridge, MA). The pathogenicity of the
variants was assessed according to the reported data and public
databases, including but not limited to, the ClinVar database
(National Institutes of Health, Bethesda, MD).
Statistical Analysis
Survival was measured from the ﬁrst date of treatment to the date
of last contact or the date of death from any cause. The Kaplan-
Meier product-limit method was used to estimate the duration of
treatment, and overall survival (OS) and hazard ratios (HRs) were
estimated using univariate Cox regression models. Patients who
received oxaliplatin therapy in the adjuvant setting were excluded
from analyses of ﬁrst-line metastatic oxaliplatin survival but were
included in the analyses for ﬁrst-line irinotecan, because most of
these patients had received adjuvant oxaliplatin. All tests were 2-
sided, and P  .05 was considered to indicate statistical signiﬁ-
cance. Descriptive statistics and survival analyses were performed
using Stata, version 13.1.
Results
Patient Characteristics
A total of 223 colorectal cancer patients were included in the
present study and had tissue available for analysis for ATM IHC
(Figure 1). The patient characteristics and treatment history are
listed in Table 1. Adjuvant oxaliplatin was used in 66 patients
(30%), of whom, 50 (76% of 66) were treated with ﬁrst-line
irinotecan and included in all analyses. Twelve patients treated
with adjuvant oxaliplatin were rechallenged with the same agent inClinical Colorectal Cancer December 2018 - 281
Table 1 Patient Characteristics
Characteristic n (%)
Total patients 223 (100)
Age, y
Median 60
Range 19-86
Male gender 133 (60)
De novo metastatic disease from diagnosis 137 (61)
Interval from diagnosis to metastatic disease, mo
Median 13
Range 2-170
Treatment lines, n
Median 3
Range 1-7
First exposure to oxaliplatin
Adjuvant/neoadjuvant 66 (30)
First-line metastatic 122 (55)
Second-line metastatic 29 (13)
Third-line and beyond 5 (2)
First-line metastatic oxaliplatin regimensa
CAPOX 38 (31)
FOLFOX/bevacizumab 31 (25)
FOLFOX 21 (17)
CAPOX/bevacizumab 16 (13)
FOLFOX/cetuximab 9 (7)
First exposure to irinotecan
First-line metastatic 82 (36)
Second-line metastatic 114 (51)
First-line metastatic irinotecan regimensb
FOLFIRI/cetuximab 29 (35)
FOLFIRI/bevacizumab 26 (32)
FOLFIRI 10 (12)
Abbreviations: CAPOX ¼ capecitabine, oxaliplatin; FOLFIRI ¼ folinic acid, 5-ﬂuorouracil, iri-
notecan; FOLFOX ¼ folinic acid, 5-ﬂuorouracil, oxaliplatin.
aPercentages computed from 122 patients.
bPercentages computed from 82 patients.
Table 2 Comparison of Therapies Received Stratiﬁed by ATM
IHC Status
Therapy
ATM IHC Loss
(n [ 17)
ATM IHC Proﬁcient
(n [ 206)
Adjuvant oxaliplatin 6 (35) 60 (29)
First-line metastatic
oxaliplatin
9 (53) 113 (55)
With bevacizumab 3 (33% of 9) 45 (40% of 113)
With cetuximab 0 (0) 10 (9% of 113)
First-line metastatic
irinotecan
7 (41) 75 (36)
Adjuvant oxaliplatin 5 (71% of 7) 45 (60% of 75)
With bevacizumab 3 (43% of 7) 33 (44% of 75)
With cetuximab 2 (29% of 7) 28 (37% of 75)
Data presented as n (%).
Abbreviations: ATM ¼ ataxia telangiectasia mutated; IHC ¼ immunohistochemistry.
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involving oxaliplatin survival. Four patients were treated with oxa-
liplatin in the adjuvant setting and had received neither irinotecan
nor oxaliplatin in the metastatic setting. Five patients were treated in
the ﬁrst-line setting with non-irinotecan/oxaliplatinebased regi-
mens. No signiﬁcant differences were found between the ATM-loss
group and the ATM-proﬁcient group regarding treatment with
targeted therapy (Table 2).
ATM IHC Protein Loss, RAS, RAF, and Mismatch Repair
Status
ATM IHC protein loss occurred in 17 cases (8%). A matched
primaryemetastatic sample was available for 19 cases and matched
metastaticemetastatic samples were available for 4 cases. No
discordance was seen in the ATM scores between the primary and
metastatic sites or between the metastatic sites. Next generation
sequencing (NGS) was performed on 213 samples (96%), of whichClinical Colorectal Cancer December 201815 failed the quality control assessment, resulting in 198 samples
with analyzable results. ATM mutations were detected in 10 cases
(5%). Of these 10 cases, 5 were nonsynonymous mutations and 5
were truncating mutations. Of the 17 cases with ATM IHC loss,
NGS was performed for 15, of which 4 (24%) were found to have
ATM mutations.
RAS and RAF mutation information was available for 212 sub-
jects. RAS mutations were reported in 119 cases (56%), with KRAS
found in 113. BRAF mutations occurred in 12 (6%). Of the 17
patients with ATM IHC loss, 9 had mutations in KRAS (53%) and
1 in BRAF (6%). Mismatch repair (MMR) deﬁciency status data,
detected through IHC, or microsatellite instability, detected by
polymerase chain reaction, were available for 44 patients, of whom,
4 were found to be MMR deﬁcient (9%; 4 of 44). One patient with
absence of MLH1 and PMS2 staining on IHC was found to have an
ATM IHC score of 0.
ATM Loss and Clinical Outcomes With Chemotherapy
Of the 121 patients who received oxaliplatin-based chemotherapy
in the ﬁrst-line metastatic setting, those with ATM IHC loss had
superior OS (49 vs. 32 months; HR, 2.52; 95% conﬁdence interval
[CI], 1.00-6.37; P ¼ .05). However, there was no statistically sig-
niﬁcant difference in OS among the 81 patients treated with ﬁrst-
line irinotecan-based therapy (24 vs. 33 months; HR, 0.72; 95%
CI, 0.28-1.84; P ¼ .49). Also, no difference was found in survival
between ﬁrst-line oxaliplatin therapy and ﬁrst-line irinotecan ther-
apy in the present cohort when ATM status was not considered (34
vs. 33 months; HR, 0.93; 95% CI, 0.62-1.39), consistent with
historical data.8 ATM IHC loss was not signiﬁcantly associated with
survival from diagnosis for the entire cohort (50 vs. 44 months; HR,
1.43; 95% CI, 0.75-2.73; P ¼ .28). Kaplan-Meier plots are
displayed in Figure 2.
Discussion
To date, precision medicine in colorectal cancer is largely
based on negative predictive biomarkers such as RAS mutational
status, precluding the use of anti-EGFR antibodies.9 Therapies
for other predictive biomarkers such as BRAF and HER2 are
Figure 2 Correlation Between Ataxia Telangiectasia Mutated (ATM) Loss and Survival With Oxaliplatin or Irinotecan. (A) Kaplan-Meier
Plot of Overall Survival of Colorectal Cancer Patients Treated With First-line Oxaliplatin-based Chemotherapy. (B) Kaplan-
Meier Plot of Overall Survival of Colorectal Cancer Patients Treated With First-line Irinotecan-based Chemotherapy. (C)
Kaplan-Meier Plot of Overall Survival of Colorectal Cancer Patients From Diagnosis (Irrespective of Treatment)
CI ¼ conﬁdence interval; HR ¼ hazard ratio; IHC ¼ immunohistochemistry.
Raghav Sundar et alcurrently under development; BRAF and HER2 constitute
w10% of all metastatic colon cancer cases. In our study, we
found that ATM protein occurs in 8% of colorectal cancer cases
and appears to be independent of RAS and RAF mutational
status. ATM loss has been described in various tumor groups. In
gastric cancer, ATM loss occurs in w20% of the population.10
ATM was studied as a potential biomarker in gastric cancer for
treatment with olaparib, a PARP (poly ADP-ribose polymerase)
inhibitor. Although the results from an initial phase II study
appeared promising,11 those from a subsequent randomized phase
III study were negative.12 Biologically and clinically more relevant
might be the synthetic lethality of ATM deﬁciency with ATR
inhibition. ATR inhibitors are currently being evaluated, and an
ATM assay could be useful to predict response to therapy. In a
phase I study of VX-907, an ATR inhibitor, a patient with ATM
loss colorectal cancer had a complete response to single-agent
therapy.4 Our results have shown that patients with ATM
IHC loss colorectal cancer have a better outcome when treated
with oxaliplatin-based therapy, consistent with preclinical data. As
more DNA damage response targeting agents enter clinical trials,
the use of ATM aberrancies as predictive biomarkers for these
therapies will increase. It is possible that identiﬁcation of ATM
deﬁciency either through IHC or NGS will be incorporated into
routine clinical biomarker testing, in addition to RAS, RAF and
MMR in colorectal cancer in the future.
Conclusion
We have described the occurrence of ATM IHC loss in a large
cohort of patients with colorectal cancer and its correlation with
several other clinical relevant parameters such as RAS and RAF
status. We have also demonstrated the improved clinical outcomes
of patients with ATM IHC loss colorectal cancer when treated with
oxaliplatin-based therapy. ATM could be considered as a potential
predictive biomarker for the development of novel DNA repair
targeted therapy for colorectal cancer.Clinical Practice Points
 DNA damage repair is emerging as a promising pathway to be
targeted in several cancer subtypes such as breast and ovarian
cancer.
 ATM and ATR are key proteins involved in DNA damage
repair.
 ATM loss has been reported to occur in w20% of cases of
gastric cancer.
 Randomized studies with drugs targeting DNA damage repair
have incorporated ATM as a potential biomarker to select for
gastric cancer patients who might beneﬁt from this form of
therapy.
 The prevalence of ATM loss in colorectal cancer has previously
never been described in a large cohort.
 In our cohort of> 200patients, 8%were reported tohaveATMloss
as measured by protein expression, using immunohistochemistry.
 ATM loss appears to be independent of RAS and RAF muta-
tional status.
 In our cohort, ATM loss in colorectal cancer resulted in superior
overall survival when treated with ﬁrst-line oxaliplatin
chemotherapy.
 ATM could be considered as a potential predictive biomarker for
the development of novel DNA repair-targeted therapy for
patients with refractory colorectal cancer.Acknowledgments
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